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a  b  s  t  r  a  c  t
Arboviruses  are  medically  important  pathogens  that cause  human  disease  ranging  from  a mild  fever  to
encephalitis.  Laboratory  diagnosis  is  essential  to differentiate  arbovirus  infections  from  other  pathogens
with  similar  clinical  manifestations.  The  Arboviral  Diseases  Branch  (ADB)  reference  laboratory  at  the CDC
Division of Vector-Borne  Diseases  (DVBD)  produces  reference  antigens  used  in serological  assays  such
as the  virus-speciﬁc  immunoglobulin  M antibody-capture  enzyme-linked  immunosorbent  assay  (MAC-
ELISA). Antigen  production  in  cell  culture  has  largely  replaced  the  use  of suckling  mice;  however,  the
methods  are  not  directly  transferable.  The  development  of  a cell  culture  antigen  production  algorithm
for  nine  arboviruses  from  the  three  main  arbovirus  families,  Flaviviridae,  Togaviridae,  and  Bunyaviridae,mmunoglobulin M antibody-capture
nzyme-linked immunosorbent assay
MAC-ELISA)
eta-propiolactone
amma-irradiation
is described  here.  Virus  cell  culture  growth  and  harvest  conditions  were  optimized,  inactivation  meth-
ods were evaluated,  and  concentration  procedures  were  compared  for each  virus.  Antigen  performance
was  evaluated  by the  MAC-ELISA  at  each  step  of  the  procedure.  The  antigen  production  algorithm  is a
framework  for standardization  of  methodology  and  quality  control;  however,  a  single  antigen  production
protocol  was  not  applicable  to  all arboviruses  and  needed  to  be  optimized  for each  virus.
Published  by Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY-NC-ND  license. Introduction
There are over 500 arthropod-borne viruses, or arboviruses, geo-
raphically distributed throughout the world, over 150 of which
ause disease in human and/or animal populations (Monath and
einz, 1996; Burke and Monath, 2001; Gubler, 2002; Weaver,
005; Cleton et al., 2012; Rosenberg et al., 2013; Centers for
isease Control and Prevention, 2014). Some arboviruses, such
s dengue, Japanese encephalitis, and most recently chikungunya
CHIK) viruses, have wide geographical distribution and cause large
easonal epidemics (Powers et al., 2000; Staples et al., 2009). Oth-
rs, such as West Nile virus, Zika virus and again, CHIK virus,
re emerging or reemerging, and may  cause sporadic outbreaks
n regions in which they were not previously detected (Lanciotti
t al., 1999; Solomon and Winter, 2004; Lanciotti et al., 2007, 2008).
ther arboviruses, such as Powassan (POW), have low or unknown
ncidence, and may  be detected due to emergence or increased
urveillance (Ei Khoury et al., 2013).
∗ Corresponding author. Tel.: +1 970 225 4217.
E-mail address: bvv0@cdc.gov (C.H. Goodman).
ttp://dx.doi.org/10.1016/j.jviromet.2014.07.030
166-0934/Published by Elsevier B.V. This is an open access article under the CC BY-NC-N(http://creativecommons.org/licenses/by-nc-nd/3.0/).
Arbovirus infections may  present with clinical symptoms sim-
ilar to those of other bacterial or virological infections, such as
an inﬂuenza-like illness, encephalitis, or polio-like myelitis (Burke
and Monath, 2001). In addition, arboviruses within a serocomplex
may  cause similar disease syndromes and may  be clinically indis-
tinguishable from one another. Laboratory diagnosis is necessary
to identify arbovirus infections and differentiate between other
bacterial or viral pathogens, particularly if there is an effective
treatment or vaccine available. The virus-speciﬁc immunoglobulin
M (IgM) antibody-capture enzyme-linked immunosorbent assay
(MAC-ELISA) can be used for rapid detection of acute arbovirus
infections, as IgM antibody is produced early in infection, rises
rapidly to detectable levels, and is less cross-reactive than IgG anti-
bodies (Johnson et al., 2000; Martin et al., 2000; WHO,  2003; Wong
et al., 2003, 2004; Johnson et al., 2005). The CDC Division of Vector-
Borne Diseases (DVBD) Arboviral Diseases Branch (ADB) reference
laboratory produces antigens for the MAC-ELISA for a wide array of
arboviruses, most of which are not available commercially.Viral antigen used in serological assays was previously gener-
ated from sucrose-acetone extracted suckling mouse brain (SMB)
preparations. In order to reduce the use of animals, viral antigen
production has shifted toward cell culture. This has necessitated
D license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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odiﬁcation and optimization of the methods previously used
uring SMB  antigen production to cell culture, such as virus inacti-
ation and concentration. The development of a cell culture antigen
roduction algorithm for nine arboviruses from the three main
rbovirus families, Flaviviridae, Togaviridae, and Bunyaviridae, is
eported here. Cell culture conditions and inactivation and con-
entration procedures were optimized for each virus, using the
AC-ELISA as the performance indicator.
. Materials and methods
.1. Viruses
Yellow fever virus (YFV) strain 17D; St. Louis encephalitis virus
SLEV) strain TBH-28; Powassan virus (POWV) strain LB; Chikun-
unya virus (CHIKV) strains 181/25 and S27; Mayaro virus (MAYV)
train TR15537; Sindbis virus (SINV) strains EgAr 339, 16260, 80-
449, AUS C 263, AUS C 377, AUS MRM  39, INDA 1036, MAL  AMM
215, Michalovce, Reed Warbler, SAAR 86 and UGMP 684; La Crosse
irus (LACV) strain Original; Jamestown Canyon virus (JCV) strains
1V-2235 and MN256-260; and Tahyna virus (TAHV) strain Bar-
os 92 were obtained from the Arbovirus Reference Collection at
he Centers for Disease Control and Prevention (CDC), Division of
ector-Borne Diseases (DVBD) in Fort Collins, Colorado.
.2. Tissue culture
Cell lines used in the growth curves were obtained at CDC DVBD.
frican green monkey kidney (Vero) cells, baby hamster kidney
BHK-21) clones 13 and 15 cells, rhesus monkey kidney (LLC-MK2)
ells, and Vero clone E6 cells were maintained at 37 ◦C in Dulbecco’s
odiﬁed Eagle Medium (DMEM, Life Technologies, Grand Island,
Y) with 8% fetal bovine serum (FBS, Atlas Biologicals, Fort Collins,
O), 1 mM sodium pyruvate (Life Technologies), 27 mM  sodium
icarbonate (Life Technologies), 0.1 mM gentamicin (Lonza, Walk-
rsville, MD), and 1 M amphotericin B (Sigma–Aldrich, St. Louis,
O). Aedes albopictus mosquito C6/36 cells were maintained at
8 ◦C in DMEM (Life Technologies) with 10% FBS (Atlas Biologi-
als), 0.1 mM non-essential amino acids (Life Technologies), 1 mM
odium pyruvate (Life Technologies), 9 mM sodium bicarbonate
Life Technologies), and 0.1 mM gentamicin (Lonza).
.3. Growth curves
Growth curves were performed in T150-cm2 cell culture ﬂasks
Corning Inc. Life Sciences, Tewksbury, MA)  at a multiplicity of
nfection (MOI) ranging from 0.0005 to 0.1 plaque-forming units
PFU)/cell. Following adsorption of virus in 10 ml  of media at 37 ◦C
or 1 h, cells were maintained in 60 ml  of their respective media as
escribed above, albeit with 2% FBS (Atlas Biologicals). At 24 h inter-
als, 0.5–1.0 ml  of supernatant was removed and frozen at −70 ◦C
ntil tested. Growth curves were carried out for 3–16 days until
ytopathic effect (CPE) reached ∼90–100%, or until the cells became
vergrown in the negative control ﬂask.
.4. Virus titration
Virus titers were determined by 1% agarose double-overlay
laque titration assay in Vero cells, as previously described (Beaty
t al., 1995). Plaques were visualized with second overlays applied
ith 0.005% neutral red (Sigma–Aldrich) following incubation for
 days for CHIKV, MAYV, SINV, LACV, and TAHV; 3 days for JCV;
 days for YFV; and 6 days for SLEV and POWV. Virus titers were
ecorded as log10 PFU/ml.ical Methods 208 (2014) 66–78 67
2.5. IgM antibody-capture enzyme-linked immunosorbent assay
(MAC-ELISA)
Viral antigen activity was evaluated by the CDC MAC-ELISA, as
previously described (Martin et al., 2000). Live virus or inactivated
antigen was serially diluted twofold and reacted against both con-
stant IgM positive and normal control sera, obtained from the DVBD
diagnostic laboratory, except the SINV IgM positive control, for
which no human sera was  available. An alphavirus-group reactive
mouse/human chimeric monoclonal antibody (cMAb) served as the
SINV IgM positive control (Thibodeaux et al., 2011). Virus-speciﬁc
antigen activity (VSAA) was  deﬁned as the optical density (OD)
of viral antigen reacted against a constant positive control serum;
acceptable VSAA had an OD of >0.8. Nonspeciﬁc background reac-
tivity (NBR) was deﬁned as the OD of viral antigen reacted against a
constant normal control serum; acceptable NBR had an OD  of <0.2.
A satisfactory antigen was deﬁned as that which had acceptable
MAC-ELISA results, in which both the VSAA and NBR were within
acceptable OD ranges; the highest antigen dilution with accept-
able VSAA and NBR OD ranges was considered the working antigen
dilution, and was a measure of functional antigen concentration.
2.6. Virus production for inactivation and concentration analyses
The optimal virus strain, cell type, and day of harvest were deter-
mined by the growth curves from one T150-cm2 ﬂask, after which a
second batch was  made in additional T150-cm2 ﬂask(s) under the
optimized conditions. Supernatant was  harvested, with volumes
ranging from 60 to 500 ml,  clariﬁed at 2400 × g for 10 min at 4 ◦C,
and stored at −70 ◦C with 20% FBS (Atlas Biologicals) until further
analysis. Flaviviruses grow relatively slowly and it was possible to
collect and replenish supernatant on multiple days from one ﬂask.
The harvests were then combined to make one batch.
2.7. Virus inactivation methods
2.7.1. Beta-propiolactone (BPL)
Cell culture supernatants were thawed in a 44 ◦C water bath
with intermittent shaking, treated with BPL (CTC Organics, Atlanta,
GA) at ﬁnal concentrations ranging from 0.01% to 0.3%, and incu-
bated for 24 h at 4 ◦C with moderate shaking on a refrigerated
shaker plate. Mock-treated control supernatants (no addition of
BPL) were incubated under the same conditions as the BPL-treated
samples. Due to acidic BPL by-products, 7.5% sodium bicarbon-
ate (Life Technologies) was  added intermittently to adjust the pH
(French and McKinney, 1964). Following BPL treatment the samples
were stored at −70 ◦C until further analysis. For hydrolysis analysis,
samples were treated with 0.05 or 0.3% BPL and incubated for 48 h
at 4 ◦C with moderate shaking. Following BPL treatment, samples
that underwent hydrolysis were incubated at 37 ◦C for 2 h, and then
placed at −70 ◦C until further analysis.
2.7.2. Gamma-irradiation
Gamma-irradiation using a cobalt-60 source was carried out at
the CDC irradiation facility in Atlanta, GA. Small volume aliquots of
virus were irradiated with doses ranging from 1 to 6 Mrad in a “kill
curve.” All material was maintained frozen on dry ice throughout
the treatment process. Untreated control supernatants remained
frozen without any exposure to gamma-irradiation.
2.7.3. Gamma-irradiation + BPL
Virus supernatant was treated with 5.5–6 Mrad, thawed, con-
centrated 5× to 6× with Centricon Plus-70,100 kDa Centrifugal
Filter Devices (Millipore), and then treated with BPL at ﬁnal con-
centrations ranging from 0.01% to 0.1%.
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.7.4. 37% Formaldehyde (Formalin)
Cell culture supernatants were treated with 0.05% to 0.3% ﬁnal
oncentrations of 37% formalin (Fisher Scientiﬁc, Waltham, MA)
nd incubated for 4.5 days at 4 ◦C, room temperature, or 37 ◦C with
oderate shaking or stirring (Sabin, 1943). Aliquots were taken at
, 12, 24, 36, 48, 72, 96, and 108 h and tested for antigen activity.
.7.5. Hydrogen peroxide
Cell culture supernatants were treated with a 3% ﬁnal concentra-
ion of hydrogen peroxide (Fisher Scientiﬁc) and incubated for 2 h at
oom temperature with moderate shaking, as described (Amanna
t al., 2012). To adjust for pH changes, 7.5% sodium bicarbonate
Life Technologies) was added intermittently during incubation.
.7.6. N-Lauroylsarcosine sodium salt (Sarkosyl)
Cell culture supernatants were treated with 0.1% to 0.3% ﬁnal
oncentrations of sarkosyl (Sigma–Aldrich) and incubated for 1 h
t room temperature, as previously described (Piret et al., 2002a,b).
rior to treatment, the sarkosyl stock solution was ﬁltered through
 Millex GV PVDF 0.22-m membrane (Millipore, Billerica, MA)  for
terilization purposes.
.8. Antigen concentration methods
.8.1. Ultracentrifugation
Inactivated cell culture supernatants were concentrated by
ltracentrifugation at 54,000 × g at 4 ◦C for ∼16 h. Super-
atant was completely removed and pelleted antigen was
esuspended in 0.1 M trizma/BS buffer: 1.0 M trizma pH 9.0
Sigma–Aldrich) + borate saline solution pH 9.0 [1.5 M sodium chlo-
ide (Daigger, Vernon Hills, IL), 0.5 M boric acid (Fisher Scientiﬁc),
.0 N sodium hydroxide (Daigger)], or 1× phosphate buffered saline
PBS, Life Technologies) to achieve the desired concentration factor.
.8.2. Centrifugal ﬁlters
Inactivated cell culture supernatants were concentrated in
micon Ultra-15,100-kDa Centrifugal Filter Devices (Millipore) or
entricon Plus-70,100-kDa Centrifugal Filter Devices at 3500 × g
or 10–45 min  at 4 ◦C. Any material that was inadvertently concen-
rated beyond the desired concentration factor was  diluted to the
orrect volume with 0.1 M trizma/BS buffer or 1× PBS.
.9. Infectivity assays
Two methods were used to evaluate infectivity of inactivated
ntigen as described previously with modiﬁcations (Monath et al.,
010). Brieﬂy, plaque titration of the treated antigen material was
erformed in duplicate in 6-well plates on Vero cells, beginning at
eat concentration. In addition, 100 l of treated antigen was inoc-
lated into duplicate T25-cm2 cell culture ﬂasks containing Vero or
HK-21c.15 cells and passaged once a week for 3 weeks. Virus was
onsidered inactivated if there was no detectable titer by plaque
itration and if there was no detectable CPE in any of the three cell
ulture passages.
. Results
.1. Growth curves
Virus growth curves were performed ﬁrst to determine the opti-
al  virus strain and cell culture type to use for subsequent antigen
roduction. Viruses were inoculated into T150-cm2 ﬂasks at MOIs
anging from 0.0005 to 0.1 and incubated for 3–16 days, depend-
ng on CPE and the condition of the cell monolayer. Supernatant,
.5–1 ml,  was removed at 24 h time points and tested by plaque
itration and/or MAC-ELISA. The growth and harvest conditionsical Methods 208 (2014) 66–78
resulting in the highest titer and/or greatest acceptable antigen
activity were chosen to make a second batch, which was used in the
inactivation and concentration analyses. If multiple conditions gen-
erated the highest titer and/or greatest acceptable antigen activity
equally (e.g. POWV produced from Vero and BHK-21 cells both gen-
erated the highest VSAA), the cell culture that yielded more product
(as in performing multiple collections), was chosen. Second-batch
product was evaluated by MAC-ELISA to conﬁrm acceptable VSAA
and NBR ranges prior to inactivation experiments; the results are
shown in Table 1 (untreated).
3.1.1. Flaviviruses
3.1.1.1. Yellow fever virus. YFV strain 17D was  inoculated into Vero
and BHK-21c.15 cells at an MOI  of 0.01 and incubated for 8 days.
YFV grown in Vero cells had the highest titer of 8.3 log10 PFU/ml at
day 4 (Fig. 1A). The second batch of YFV was grown in Vero cells
and supernatant was  replaced and harvested on days 4, 5, and 6
and the three collections were combined into one batch. The VSAA
and NBR of YFV were acceptable and the working antigen dilution
was 1:32 (Table 1A, untreated).
3.1.1.2. St. Louis encephalitis virus. SLEV strain TBH-28 was  inoc-
ulated at an MOI  of 0.01 into Vero, BHK-21c.13, and BHK-21c.15
cells, and at an MOI  of 0.1 into Vero cells. BHK-21c.13 and BHK-
21.15 cells were incubated for 4 days and Vero cells were incubated
for 11 days. Titers of approximately 7 log10 PFU/ml were similar in
Vero (MOI = 0.1) and BHK-21c.13 cells at day 3 (Fig. 1B). Vero cells
(MOI = 0.1) were selected for second batch production, and super-
natant was  replaced and harvested on days 3 and 4 and combined
into one batch. The VSAA and NBR of SLEV were acceptable and the
working antigen dilution was  1:8 (Table 1B, untreated).
3.1.1.3. Powassan virus. POWV strain LB was  inoculated at an MOI
of 0.01 and incubated for 16 days in Vero and LLC-MK2 cells and for
4 days in BHK-21c.13 and BHK-21c.15 cells. Peak titers of approxi-
mately 8 log10 PFU/ml were similar in Vero cells at days 6–9 and in
BHK-21c.13 cells at day 2 (Fig. 1C). Time point aliquots were also
tested by the POWV MAC-ELISA to determine peak VSAA. POWV
produced from Vero cells and collected on day 6 yielded higher
VSAA compared to those obtained from BHK-21c.13, BHK-21c.15,
and LLC-MK2 cells (working antigen dilutions of 1:32, unusable,
unusable, and 1:8, respectively), and was therefore selected for sec-
ond batch production, with supernatant replaced and harvested
on days 5, 6, and 7 and combined into one batch. The VSAA and
NBR were acceptable and the working antigen dilution was 1:16
(Table 1C, untreated).
3.1.2. Alphaviruses
3.1.2.1. Chikungunya virus. CHIKV strains 181/25 and S27 were
inoculated into Vero and BHK-21c.15 cells at an MOI  of 0.001 and
incubated for 4 days, and into C6/36 cells at an inadvertent MOI  of
0.0005 and incubated for 5 days. Peak titers were between 8 and
10 log10 PFU/ml in all cell types (Fig. 1D). Time point aliquots tested
by the CHIKV MAC-ELISA showed variation in the VSAAs, which did
not correspond to the titers. Representative CHIKV titer and MAC-
ELISA results are shown in Table 2. CHIKV strain 181/25 grown in
C6/36 cells and CHIKV strain S27 grown in BHK-21c.15 cells were
the only two preparations to yield both acceptable VSAA and NBR;
other CHIKV strain/cell type combinations yielded VSAA below the
acceptable range, despite the high titers (Fig. 1D). CHIKV strains
181/25 and S27 were both grown in C6/36 cells and had equivalent
titers of 10.3 log10 PFU/ml, but only strain 181/25 had acceptable
VSAA. CHIKV strain S27 grown in Vero and BHK-21c.15 cells had
nearly equivalent titers of 9.4 and 9.3 log10 PFU/ml, respectively;
however, only strain S27 grown in BHK-21c.15 cells had acceptable
VSAA. Second batches were produced from CHIKV strain 181/25
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Table  1
Antigen reactivity in MAC  ELISA before (untreated) and after inactivation.
(A) YFV/17D/Vero*
Antigen dilution VSAA NBR VSAA NBR VSAA NBR VSAA NBR
0.01% BPL 0.05% BPL 0.1% BPL Mock-treated
1:10  2.840 0.064 3.091 0.188 3.205 1.900 2.706 0.047
1:20  2.162 0.047 2.367 0.112 2.009 1.058 2.050 0.042
1:40  1.569 0.045 1.631 0.068 1.415 0.668 1.399 0.039
1:80  1.024 0.038 1.003 0.064 0.762 0.402 0.882** 0.039
1:160 0.587 0.038 0.550 0.056 0.431 0.254 0.519 0.034
1:320  0.339 0.043 0.281 0.079 0.235 0.159 0.301 0.036
1  Mrad 3 Mrad 5 Mrad Untreated
Neat  2.497 0.019 2.536 0.029 2.167 0.034 2.636 0.099
1:2  2.290 0.021 2.310 0.057 1.835 0.037 2.533 0.087
1:4  1.857 0.020 1.877 0.049 1.432 0.030 2.174 0.021
1:8  1.453 0.015 1.290 0.037 1.041† 0.025 1.759 0.018
1:16  0.866‡ 0.017 0.819 0.049 0.688 0.031 1.194 0.018
1:32  0.701 0.015 0.540 0.051 0.429 0.030 0.859 0.025
(B) SLEV/TBH-28/Vero
Antigen dilution VSAA NBR VSAA NBR VSAA NBR VSAA NBR
0.01% BPL 0.05% BPL 0.1% BPL Mock-treated
1:10  0.819 0.037 0.812 0.059 0.844 0.051 0.757 0.033
1:20  0.492 0.032 0.472 0.035 0.490 0.038 0.455 0.030
1:40  0.272 0.031 0.276 0.028 0.273 0.034 0.259 0.028
1:80  0.156 0.027 0.157 0.026 0.162 0.026 0.150 0.026
1:160  0.097 0.028 0.097 0.024 0.102 0.028 0.089 0.026
1:320  0.063 0.031 0.059 0.024 0.072 0.028 0.060 0.027
1  Mrad 3 Mrad 5 Mrad Untreated
Neat 2.454 0.068 1.823 0.078 1.563 0.066 2.267 0.034
1:2  2.432 0.045 1.880 0.073 1.600 0.085 2.108 0.018
1:4  2.022 0.046 1.531 0.054 1.346 0.063 1.691 0.015
1:8  1.335 0.038 1.026 0.034 0.868 0.038 1.201 0.016
1:16 0.722 0.031 0.568 0.023 0.443 0.021 0.634 0.013
1:32  0.387 0.029 0.283 0.018 0.221 0.017 0.292 0.012
(C)  POWV/LB/Vero
Antigen dilution VSAA NBR VSAA NBR VSAA NBR VSAA NBR VSAA NBR
0.01% BPL 0.05% BPL 0.1% BPL Mock-treated Untreated
Neat  2.113 0.025 1.949 0.031 2.366 0.116 2.325 0.022 2.824 0.027
1:2  1.907 0.021 2.045 0.027 2.112 0.053 2.070 0.017 2.606 0.023
1:4  1.660 0.018 1.801 0.018 1.863 0.029 1.684 0.015 2.252 0.023
1:8  1.317 0.016 1.575 0.018 1.573 0.023 1.366 0.015 1.614 0.025
1:16  1.143 0.017 1.286 0.016 1.285 0.021 1.006 0.014 1.165 0.022
1:32 0.762 0.015 0.763 0.017 0.778 0.020 0.748 0.016 0.873 0.023
(D)  CHIKV/181-25/C6/36
Antigen dilution VSAA NBR VSAA NBR VSAA NBR VSAA NBR
0.1% BPL 0.2% BPL 0.3% BPL Mock-treated
1:10  1.572 0.129 1.413 0.350 1.151 0.358 0.575 0.050
1:20  1.307 0.120 0.890 0.200 0.656 0.175 0.350 0.043
1:40  1.383 0.135 0.770 0.133 0.477 0.153 0.214 0.040
1:80  1.077 0.118 0.682 0.120 0.428 0.088 0.116 0.038
1:160  0.744 0.126 0.476 0.098 0.304 0.104 0.059 0.035
1:320  0.475 0.107 0.315 0.079 0.225 0.077 0.058 0.052
1  Mrad 3 Mrad 6 Mrad Untreated
Neat  2.007 0.047 2.255 0.057 2.447 0.141 2.154 0.049
1:2  1.498 0.036 1.872 0.044 2.574 0.096 1.944 0.045
1:4  0.977 0.036 1.352 0.044 2.521 0.088 1.427 0.040
1:8  0.782 0.037 1.081 0.044 2.259 0.086 1.151 0.040
1:16  0.705 0.042 0.994 0.053 1.916 0.135 1.145 0.045
1:32  0.735 0.049 0.904 0.066 1.538 0.119 1.020 0.052
CHIKV/S27/BHK-21c.15
1 Mrad 3 Mrad 5 Mrad Untreated
Neat  2.262 0.036 3.293 0.097 3.527 0.141 1.055 0.030
1:2  2.094 0.036 3.247 0.054 3.311 0.070 1.078 0.030
1:4  1.753 0.034 2.982 0.039 3.014 0.044 0.813 0.028
1:8 1.142 0.032 2.394 0.039 2.564 0.054 0.451 0.025
1:16  0.669 0.036 1.763 0.035 1.876 0.058 0.273 0.027
1:32  0.471 0.030 1.131 0.030 1.184 0.036 0.183 0.028
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Table  1 (Continued)
(D) CHIKV/181-25/C6/36
Antigen dilution VSAA NBR VSAA NBR VSAA NBR VSAA NBR
0.1% BPL 0.2% BPL 0.3% BPL Mock-treated
5.5  Mrad + 0.01% BPL 5.5 Mrad + 0.05% BPL 5.5 Mrad + 0.1% BPL 5.5 Mrad only
1:10  3.324 0.061 3.647 0.833 3.591 1.892 3.007 0.038
1:20  3.072 0.042 3.445 0.503 3.577 0.970 2.740 0.034
1:40  2.718 0.040 3.225 0.433 3.208 0.803 2.409 0.032
1:80  2.072 0.039 2.777 0.358 2.709 0.732 1.789 0.030
1:160 1.354 0.037 1.953 0.264 1.671 0.506 1.119 0.022
1:320  0.827 0.033 1.211 0.154 1.225 0.356 0.652 0.020
(E)  MAYV/TR15537/BHK-21c.15
Antigen dilution VSAA NBR VSAA NBR VSAA NBR VSAA NBR
0.1% BPL 0.2% BPL 0.3% BPL Mock-treated
1:4  1.868 0.035 1.245 0.079 0.670 0.151 1.619 0.028
1:8  1.265 0.031 0.924 0.046 0.466 0.057 0.906 0.027
1:16 0.804 0.032 0.716 0.037 0.338 0.048 0.511 0.030
1  Mrad 3 Mrad 6 Mrad Untreated
1:4  2.256 0.037 1.600 0.033 2.697 0.052 0.854 0.039
1:8 1.552 0.044 2.200 0.038 2.411 0.065 0.783 0.036
1:16  1.023 0.045 1.482 0.036 1.891 0.049 0.448 0.034
6  Mrad + 0.01% BPL 6 Mrad + 0.05% BPL 6 Mrad + 0.1% BPL 6 Mrad only
1:10  2.865 0.188 3.195 0.591 3.276 0.918 2.865 0.085
1:20  2.370 0.146 2.926 0.294 3.019 0.485 2.278 0.063
1:40  1.962 0.129 2.475 0.269 2.467 0.305 1.681 0.055
1:80  1.400 0.106 1.835 0.207 1.767 0.261 1.214 0.050
1:160  0.921 0.083 1.186 0.161 1.121 0.201 0.782 0.044
1:320  0.561 0.074 0.698 0.120 0.648 0.164 0.492 0.040
(F)  SINV/AUS MRM  39/Vero
Antigen dilution VSAA NBR VSAA NBR VSAA NBR VSAA NBR
0.1% BPL 0.25% BPL 0.3% BPL Mock-treated
1:8  1.013 0.043 0.961 0.047 0.874 0.047 0.916 0.035
1:16 0.480 0.041 0.426 0.041 0.389 0.044 0.489 0.036
1:32  0.263 0.043 0.228 0.037 0.224 0.041 0.266 0.040
1  Mrad 3 Mrad 6 Mrad Untreated
1:4  2.235 0.053 2.551 0.050 2.870 0.056 1.682 0.044
1:8  1.183 0.052 1.572 0.050 1.873 0.058 0.922 0.043
1:16 0.690 0.052 0.761 0.049 0.925 0.055 0.487 0.037
(G)  LACV/Original/BHK-21c.13
Antigen dilution VSAA NBR VSAA NBR VSAA NBR VSAA NBR VSAA NBR
0.01% BPL 0.05% BPL 0.1% BPL Mock-treated Untreated
1:10  3.102 0.121 3.324 0.209 3.133 0.107 3.142 0.124 3.217 0.100
1:20  2.837 0.116 3.092 0.143 3.014 0.101 2.523 0.104 2.488 0.097
1:40  1.912 0.100 2.365 0.111 2.433 0.094 1.543 0.102 1.594 0.092
1:80  1.149 0.115 1.452 0.092 1.639 0.106 0.944 0.099 0.971 0.088
1:160 0.659 0.084 0.777 0.105 0.863 0.086 0.568 0.103 0.569 0.055
1:320  0.390 0.105 0.464 0.109 0.508 0.105 0.360 0.106 0.346 0.077
(H)  JCV/MN256-260/BHK-21c.13
Antigen dilution VSAA NBR VSAA NBR VSAA NBR VSAA NBR VSAA NBR
0.01% BPL 0.05% BPL 0.1% BPL Mock-treated Untreated
Neat  3.038 0.100 2.481 0.078 1.829 0.064 3.218 0.112 3.210 0.098
1:2  3.308 0.104 2.833 0.076 2.064 0.066 3.319 0.100 3.140 0.112
1:4  3.035 0.111 2.572 0.079 1.938 0.079 3.134 0.106 2.820 0.102
1:8  2.605 0.097 2.155 0.079 1.709 0.080 2.687 0.095 2.219 0.089
1:16  2.097 0.095 1.709 0.080 1.347 0.081 2.138 0.095 1.487 0.082
1:32  1.521 0.087 1.155 0.073 0.945 0.073 1.557 0.097 1.004 0.055
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Table  1 (Continued)
(I) TAHV/Bardos 92/BHK-21c.13
Antigen dilution VSAA NBR VSAA NBR VSAA NBR VSAA NBR VSAA NBR
0.01% BPL 0.05% BPL 0.1% BPL Mock-treated Untreated
1:10  2.256 0.087 1.111 0.061 0.355 0.068 2.504 0.095 2.595 0.084
1:20  1.511 0.074 0.797 0.057 0.269 0.063 1.811 0.083 1.872 0.074
1:40  1.132 0.081 0.553 0.059 0.245 0.063 1.202 0.071 1.238 0.067
1:80 0.685 0.075 0.391 0.059 0.194 0.075 0.712 0.064 0.767 0.061
1:160  0.414 0.076 0.260 0.066 0.126 0.069 0.446 0.069 0.452 0.055
1:320  0.260 0.072 0.170 0.072 0.127 0.074 0.268 0.070 0.270 0.051
Abbreviations: VSAA – virus-speciﬁc antigen activity; NBR – nonspeciﬁc background reactivity.
* Virus name/strain/cell culture type.
** Underlined OD readings indicate the working antigen dilution of untreated or mock-treated, infectious antigen.
† OD readings in bold indicate the dilution of the unconcentrated antigen that yielded acceptable MAC  ELISA results; upon concentration, the antigen yielded acceptable
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rown in C6/36 cells and harvested on day 3 and CHIKV strain S27
rown in BHK-21c.15 cells and harvested on day 2: the VSAAs and
BRs were acceptable and the working antigen dilutions were 1:32
nd 1:4, respectively (Table 1D, untreated).
.1.2.2. Mayaro virus. MAYV strain TR15537 was inoculated into
ero, BHK-21.c13, and BHK-21c.15 cells at an MOI of 0.001 and
ncubated for 5 days. Peak titers were approximately equivalent at
 log10 PFU/ml in all cell types at day 2 (Fig. 1E). Aliquots were also
ested by the MAYV MAC-ELISA. MAYV grown in BHK-21c.15 cells
nd collected on day 2 yielded higher VSAA over those obtained
rom Vero and BHK-21c.13 cells (working antigen dilutions of
:8, neat, and 1:2, respectively), and was therefore selected for
roduction of the second batch. MAYV harvested on day 2 from
HK-21c.15 cells had acceptable VSAA and NBR and yielded a work-
ng antigen dilution of 1:4 (Table 1E, untreated).
.1.2.3. Sindbis virus. SINV strain EgAr 339 was  inoculated into
ero, BHK-21c.13, BHK-21c.15, and LLC-MK2 cells at an MOI  of
.001 and incubated for 4 days. Peak titers were >7 log10 PFU/ml
y day 2 in all cell types except LLC-MK2 (Fig. 1F). However, none
f the aliquots tested by the SINV MAC-ELISA yielded acceptable
SAAs (data not shown).
Therefore, additional SINV strains (16260, 80-2449, AUS C 263,
US C 377, AUS MRM  39, INDA 1036, MAL  AMM  2215, Michalovce,
eed Warbler, SAAR 86, and UGMP 684) were inoculated into Vero,
HK-21c.13, and BHK-21c.15 cells at an MOI  of 0.001 and super-
atant was collected only on day 2. In this instance, the day 2
liquots were ﬁrst tested by the SINV MAC-ELISA to determine
f any strain yielded acceptable VSAA. SINV strain AUS MRM  39
roduced from Vero and BHK-21c.13 cells were the only two prepa-
ations to yield acceptable VSAAs (working antigen dilutions of
:10 for both). Subsequently, titer was determined only for the
able 2
iter and antigen reactivity in MAC  ELISA of CHIKV strains 181/25 and S27 grown in C6/3
Antigen dilution CHIKV – C6/36 cells 
Strain 181/25
(10.3 log10 PFU/ml)
Strain S27
(10.3 log10 PFU/ml)
VSAA NBR VSAA N
Neat 1.144 0.032 0.263 0
1:2  0.956 0.010 0.220 0
1:4  0.818* 0.011 0.149 0
1:8 0.646 0.015 0.102 0
1:16  0.613 0.043 0.092 0
1:32  0.528 0.025 0.054 0
bbreviations: VSAA – virus-speciﬁc antigen activity; NBR – nonspeciﬁc background react
* Underlined OD readings indicate the working antigen dilution of untreated, infectiou(s) used for ﬁnal antigen production.
d acceptable MAC ELISA results; however, the preparation had unacceptable NBR
day 2 aliquot of SINV strain AUS MRM  39 produced from Vero cells
(Fig. 1F), and SINV strain AUS MRM  39 was  selected for second batch
production. SINV strain AUS MRM  39 harvested on day 2 from Vero
cells had acceptable VSAA and NBR and yielded a working antigen
dilution of 1:8 (Table 1F, untreated).
3.1.3. Bunyaviruses
3.1.3.1. La Crosse virus. LACV strain Original was inoculated into
Vero, BHK-21.c13, and BHK-21c.15 cells at an MOI  of 0.01 and
incubated for 4 days. Peak titers were approximately equivalent at
8 log10 PFU/ml at day 2 (Fig. 1G). All time point aliquots were tested
by the LACV MAC-ELISA. LACV grown in BHK-21c.13 cells and col-
lected on day 3 yielded higher VSAA over those obtained from Vero
and BHK-21c.15 cells (working antigen dilutions of 1:160, 1:4, and
1:40, respectively), and was therefore selected for production of the
second batch. LACV grown in BHK-21c.13 cells and harvested on
day 3 had acceptable VSAA and NBR and yielded a working antigen
dilution of 1:80 (Table 1G, untreated).
3.1.3.2. Jamestown Canyon virus. JCV strain 61V-2235 was  inocu-
lated at an MOI  of 0.01 and incubated for 4 days in BHK-21c.13
and Vero E6 cells and for 5 days in Vero, BHK-21c.15, and LLC-
MK2  cells. Additionally, JCV strain MN256-260 was inoculated into
BHK-21c.13 cells at an MOI  of 0.01 and supernatant was collected
only on day 3. Peak titers ranged from 7 to 9 log10 PFU/ml at days
2–3 (Fig. 1H). Time point aliquots were also tested by the JCV
MAC-ELISA. JCV strain MN256-260 grown in BHK-21c.13 cells and
collected on day 3 yielded higher VSAA over JCV strain 61V-2235
obtained from Vero, Vero E6, BHK-21c.13, BHK-21c.15, and LLC-
MK2  cells (working antigen dilutions of 1:32, unusable, unusable,
1:16, 1:8, and unusable, respectively), and was  therefore selected
for production of the second batch. JCV strain MN256-260 har-
vested on day 3 from BHK-21c.13 cells had acceptable VSAA and
6, Vero, and BHK-21c.15 cells.
CHIKV – strain S27
Vero cells
(9.4 log10 PFU/ml)
BHK-21c.15 cells
(9.3 log10 PFU/ml)
BR VSAA NBR VSAA NBR
.010 0.125 0.020 1.116 0.017
.007 0.071 0.014 1.220 0.014
.009 0.038 0.012 0.878 0.013
.027 0.026 0.010 0.512 0.009
.036 0.022 0.013 0.303 0.012
.033 0.020 0.012 0.150 0.009
ivity.
s antigen.
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Fig. 1. Growth of (A) YFV, (B) SLEV, (C) POWV, (D) CHIKV, (E) MAYV, (F) SINV, (G) LACV, (H) JCV, and (I) TAHV in Vero, BHK-21, LLC-MK2, and C6/36 cells. T-150 cm2 ﬂasks
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BR and yielded a working antigen dilution of 1:32 (Table 1H,
ntreated).
.1.3.3. Tahyna virus. TAHV strain Bardos 92 was inoculated into
ero, BHK-21.c13, and BHK-21c.15 cells at an MOI  of 0.01 and incu-
ated for 4 days. Peak titers ranged from 7.5 to 8.5 log10 PFU/ml at
ay 2 (Fig. 1I). Time point aliquots were also tested by the TAHV
AC-ELISA. TAHV grown in BHK-21c.13 cells and collected on day
 yielded higher VSAA over those obtained from Vero and BHK-
1c.15 cells (working antigen dilutions of >1:32, 1:4, and 1:32,
espectively), and was therefore selected for production of the sec-
nd batch. TAHV harvested on day 3 from BHK-21c.13 cells had
cceptable VSAA and NBR and yielded a working antigen dilution
f 1:40 (Table 1I, untreated).
.2. Virus inactivation
Five inactivation methods were evaluated. Viruses were suc-
essfully inactivated by BPL, gamma-irradiation, or a combination
f gamma-irradiation followed by BPL. YFV, SLEV, POWV, LACV, JCV,
nd TAHV were treated with 0.01, 0.025, 0.05, 0.075, and 0.1% BPL,
nd CHIKV, MAYV, and SINV were treated with 0.1, 0.15, 0.2, 0.25,
nd 0.3% BPL. YFV, SLEV, and CHIKV strain S27 were irradiated with
–5 Mrad, and CHIKV strain 181/25, MAYV, and SINV were irradi-
ted with 1–6 Mrad. For the combination gamma-irradiation/BPL
reatments, CHIKV strain S27 and MAYV strain TR15537 were irra-
iated with 5.5 and 6 Mrad, respectively, concentrated, and then
reated with 0.01, 0.025, 0.05, 0.075, and 0.1% BPL. Representative
esults are shown in Table 1.
Inactivated antigen was evaluated in the MAC-ELISA, and rated
s acceptable or unacceptable based on VSAA and NBR. Plaque titra-
ion and passage three times in cell culture was used to rule out
esidual infectivity. The chosen inactivation method was  the one
hat completely inactivated the virus, had VSAA and NBR within
he acceptable ranges, and had the highest working antigen dilu-
ion compared to the mock-treated or untreated virus. Inactivated
irus was then concentrated to a standardized working dilution of
1:160 and re-evaluated in the MAC-ELISA and infectivity assays.
.2.1. Yellow fever virus
Unconcentrated YFV treated with ≤0.05% BPL yielded accept-
ble MAC-ELISA results (Table 1A), but was infectious at 0.01% BPL.
n addition, after concentration, the NBR of antigen treated with
.025 and 0.05% BPL rose above the acceptable limit. Unconcen-
rated YFV treated with gamma-irradiation also yielded acceptable
AC-ELISA results, but was infectious at ≤4 Mrad. Concentrated
ntigen inactivated with 5 Mrad had acceptable MAC-ELISA results,
as non-infectious, and was therefore selected as the inactivation
ethod for ﬁnal, scaled-up YFV antigen production.
.2.2. St. Louis encephalitis virus
Unconcentrated SLEV treated with ≤0.1% BPL yielded accept-
ble MAC-ELISA results (Table 1B); however, antigen treated with
.01% BPL was  infectious. Concentrated antigen inactivated with
0.05% BPL had acceptable MAC-ELISA results and remained non-
nfectious. Unconcentrated SLEV treated with gamma-irradiation
ielded acceptable MAC-ELISA results, but was infectious at
4 Mrad. Concentrated antigen inactivated with 5 Mrad had
cceptable MAC-ELISA results and was non-infectious. Due to the
ase of use of BPL over gamma-irradiation, inactivation with 0.05%
PL was selected for ﬁnal, scaled-up SLEV antigen production..2.3. Powassan virus
Unconcentrated POWV treated with ≤0.1% BPL yielded accept-
ble MAC-ELISA results (Table 1C), but was infectious at 0.01% BPL.
oncentrated antigen inactivated with ≥0.05% BPL had acceptableical Methods 208 (2014) 66–78 73
MAC-ELISA results and remained non-infectious. Inactivation with
0.05% BPL was  selected for ﬁnal, scaled-up POWV antigen produc-
tion.
3.2.4. Chikungunya virus
The VSAA of unconcentrated CHIKV strain 181/25 increased
after BPL treatment compared to mock-treated virus, which had a
VSAA below the acceptable limit (Table 1D). The greatest increase
was after 0.1% BPL treatment, with the VSAA decreasing as the BPL
concentration increased to 0.3%. All BPL concentrations completely
inactivated the virus; however, after concentration, the NBRs rose
above the acceptable limit. The VSAA of unconcentrated CHIKV
strain 181/25 treated with ≥4 Mrad also increased compared to the
untreated virus and yielded acceptable MAC-ELISA results, but all
gamma-irradiated samples were infectious.
VSAAs of unconcentrated CHIKV strain S27 increased as gamma
irradiation doses increased (Table 1D), but similar to CHIKV strain
181/25, all samples were infectious. As neither BPL nor gamma-
irradiation treatment alone completely inactivated CHIKV, CHIKV
strain S27 was treated with a combination of gamma-irradiation
followed by BPL. CHIKV strain S27 was irradiated with 5.5 Mrad,
concentrated, and then treated with ≤0.1% BPL (Table 1D). The
combination treatment of 5.5 Mrad plus ≤0.05% BPL produced
acceptable MAC-ELISA results and was non-infectious; therefore,
inactivation with 5.5 Mrad + 0.01% BPL (the lowest dose) was
selected for ﬁnal, scaled-up CHIKV antigen production.
3.2.5. Mayaro virus
Unconcentrated MAYV treated with ≤0.2% BPL yielded accept-
able MAC-ELISA results (Table 1E) and was non-infectious. Similar
to CHIKV, the VSAA of MAYV increased after 0.1% BPL treatment
compared to mock-treated MAYV and decreased as the BPL con-
centration increased to 0.3%. Concentrated antigen treated with
≥0.15% BPL produced acceptable MAC-ELISA results and was  non-
infectious, but at 0.1% BPL remained infectious. Unconcentrated
MAYV treated with gamma-irradiation also yielded acceptable
MAC-ELISA results, with increased VSAA as Mrads increased, but
was infectious at all doses. MAYV was inactivated by a combination
of gamma-irradiation followed by BPL. Unconcentrated MAYV was
irradiated with 6 Mrad, concentrated, and then treated with ≤0.1%
BPL (Table 1E), with 6 Mrad and ≤0.05% BPL yielding acceptable
MAC-ELISA and non-infectivity results.
Scale-up production of MAYV antigen with inactivation by
6 Mrad + 0.01% BPL was  performed prior to inactivation with
BPL. However, due to the ease of use of BPL over the gamma-
irradiation/BPL combination, inactivation with 0.15 or 0.2% BPL
could be used for future MAYV antigen production.
3.2.6. Sindbis virus
Unconcentrated SINV treated with ≤0.3% BPL yielded acceptable
MAC-ELISA results (Table 1F), and was non-infectious. Concen-
trated antigen treated with ≥0.15% BPL produced acceptable
MAC-ELISA results and remained non-infectious, but at 0.1% BPL
remained infectious. Unconcentrated SINV treated with gamma-
irradiation also yielded acceptable MAC-ELISA results, with VSAA
increasing as Mrads increased, but was  infectious at ≤5 Mrad. Con-
centrated antigen inactivated with 6 Mrad produced acceptable
MAC-ELISA results and remained non-infectious. Due to the ease
of use of BPL over gamma-irradiation, inactivation with 0.25% BPL
was selected for ﬁnal, scaled-up SINV antigen production.
3.2.7. La Crosse virus antigen
Unconcentrated and concentrated LACV antigen treated with
≤0.1% BPL yielded acceptable MAC-ELISA results (Table 1G), and
was non-infectious. Additionally, VSAA increased after BPL treat-
ment compared to mock-treated virus, and increased as the BPL
74 C.H. Goodman et al. / Journal of Virolog
Table  3
Comparison of antigen reactivity in MAC  ELISA of BPL-treated SLEV and CHIKV: with
or  without hydrolysis treatment.
Antigen dilution Hydrolysis No hydrolysis
VSAA NBR VSAA NBR
SLEV – 0.05% BPL
1:10 0.852 0.050 0.934 0.048
1:20 0.613 0.048 0.744 0.044
1:40 0.401 0.046 0.499 0.047
CHIKV – 0.3% BPL
1:8 1.472 0.156 1.942 0.512
1:16 0.801 0.096 1.329 0.274
1:32 0.477 0.071 0.740 0.145
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eactivity.
oncentration increased. Treatment with 0.1% BPL was  selected for
nal, scaled-up LACV antigen production.
.2.8. Jamestown Canyon virus antigen
Unconcentrated and concentrated JCV antigen treated with
0.1% BPL yielded acceptable MAC-ELISA results (Table 1H), and
as non-infectious. Even though concentrated 0.01% BPL-treated
CV material produced the highest VSAA and remained non-
nfectious during small-scale production, 0.05% BPL was  selected
or ﬁnal, scaled-up JCV antigen production to assure that the scale-
p material was completely inactivated, as 0.01% BPL had been
hown to be ineffective at inactivating the ﬂaviviruses. Also, the
orking antigen dilution could be adjusted by the concentration
actor.
.2.9. Tahyna virus antigen
Unconcentrated and concentrated TAHV treated with ≤0.05%
PL yielded acceptable MAC-ELISA results (Table 1I), and was non-
nfectious. Similar to JCV, concentrated 0.01% BPL-treated TAHV
aterial produced the highest VSAA and remained non-infectious
uring small-scale production, but 0.05% BPL was selected for ﬁnal,
caled-up TAHV antigen production to assure complete inactiva-
ion.
.2.10. Virus inactivation with formalin, hydrogen peroxide, and
arkosyl
YFV was treated with formalin at ﬁnal concentrations ranging
rom 0.05% to 0.3%. The MAC-ELISA results were acceptable, but YFV
as infectious at all formalin concentrations (data not shown).
YFV, SLEV, POWV, CHIKV, LACV, and JCV were treated with
ydrogen peroxide at a ﬁnal concentration of 3%. The VSAA
ecreased and was unacceptable in the MAC-ELISA compared to
ntreated virus (data not shown). In addition, infectivity assays of
he treated material could not be conducted, as the residual hydro-
en peroxide was  toxic to the Vero cells used in both assays (data
ot shown).
YFV, SLEV, MAYV, and LACV treated with sarkosyl at ﬁnal con-
entrations of 0.1–0.3% resulted in unacceptably low VSAA in the
AC-ELISA, and residual infectivity at all sarkosyl concentrations
data not shown).
.2.11. Hydrolysis of BPL
Aliquots of SLEV and CHIKV treated with ﬁnal concentrations of
.05 and 0.3% BPL were incubated to facilitate the complete hydrol-
sis of BPL. Hydrolyzed versus non-hydrolyzed SLEV samples had
imilar VSAA and NBR in the MAC-ELISA, and both conditions gen-
rated usable working SLEV antigen dilutions at 1:10 (Table 3). In
ontrast, the VSAA of CHIKV decreased from 1:32 to 1:16 following
ydrolysis, although the NBR decreased as well.ical Methods 208 (2014) 66–78
3.3. Antigen concentration
In order to evaluate the best method to concentrate anti-
gen to the standardized working dilution of ∼1:160, 15 ml  of
gamma-irradiated YFV antigen was  concentrated 10× and 35 ml of
BPL-inactivated SLEV antigen was concentrated 20× by ultracen-
trifugation or in centrifugal ﬁlters. Following ultracentrifugation, all
of the supernatant was removed and the antigen pellet was resus-
pended in 1.5 ml  (YFV) or 1.8 ml  (SLEV) ﬁnal volume of either 0.1 M
trizma/BS buffer or 1× PBS. During the centrifugal ﬁlter method, the
cell culture supernatant was  centrifuged until the supernatant vol-
ume  remaining in the ﬁlter reached approximately the ﬁnal volume
needed to achieve the desired concentration factor. The volume was
then adjusted to 1.5 ml  (YFV) or 1.8 ml  (SLEV) with 0.1 M trizma/BS
buffer or 1× PBS. The concentration method that resulted in the
highest working antigen dilution with both VSAA and NBR in the
acceptable ranges was  selected for future use (Fig. 2).
YFV antigen concentrated 10× by ultracentrifugation and resus-
pended in 0.1 M trizma/BS buffer or 1× PBS yielded working antigen
dilutions of 1:40 and 1:20, respectively; in contrast, concentration
by centrifugal ﬁlters yielded working antigen dilutions of 1:160
and 1:80, respectively. SLEV antigen concentrated 20× by ultracen-
trifugation and resuspended in 0.1 M trizma/BS buffer or 1× PBS
yielded working antigen dilutions of 1:40 and 1:10, respectively,
whereas centrifugal ﬁlters yielded working antigen dilutions of
1:80 in both buffers. All methods and buffers resulted in acceptable
NBR. The centrifugal ﬁlter method with volume adjustments using
0.1 M trizma/BS buffer yielded the highest concentrated product.
The remaining antigens were then concentrated 5× to 30× by cen-
trifugal ﬁlters to obtain a standard working antigen dilution of
∼1:160.
4. Discussion
CDC DVBD ADB produces and maintains an inventory of the
many arbovirus reference antigens used in serological assays. Cell
culture has largely replaced the use of animals, and inactivation
and concentration methods needed to be modiﬁed and optimized
for cell culture. The antigen production process and evaluations of
nine arbovirus antigens used in the CDC MAC-ELISA, the end-use
assay for this study, were described here. There were three each
from Flaviviridae, Togaviridae, and Bunyaviridae, and they were pro-
duced based on a prioritized list set by the diagnostic laboratory in
the following order: SLEV, YFV, CHIKV, JCV, POWV, LACV, TAHV,
MAYV, and SINV. Production of each antigen proceeded one at a
time, from growth curves to ﬁnished product, according to the algo-
rithm illustrated in Fig. 3. During the development of each antigen,
modiﬁcations were made to the methods and the procedure was
optimized based on previous antigen production results and obser-
vations, at times necessitating going back and changing methods
and repeating evaluations. Although there were trends, and in some
cases one method was  clearly superior to another for all the antigen
preparations, such as concentrating the antigen using centrifugal
ﬁlters, in general, the production method needed to be optimized
for each virus.
Additionally, antigens were produced in the most inexpensive
and time-efﬁcient manner as possible, so that if BPL treatment pro-
duced an acceptable antigen, gamma-irradiation was  generally not
pursued as a treatment option due to the expense and hands-on
time this method required. SLEV, MAYV, and SINV were the excep-
tions in that both BPL and gamma-irradiation treatments were
performed, even though acceptable antigens were produced by BPL.
SLEV was  one of the ﬁrst antigens produced, and was included in the
batch of YFV and CHIKV samples that were gamma-irradiated out
of necessity. MAYV and SINV were preemptively sent for gamma
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Fig. 2. Comparison of ultracentrifugation and centrifugal ﬁlter concentration methods. (A) Yellow fever virus inactivated by gamma-irradiation was concentrated 10×;  (B)
S
i
b
c
s
t
t
b
vt.  Louis encephalitis virus inactivated with BPL was concentrated 20×.
rradiation treatment because these alphaviruses were assumed to
ehave similarly to CHIKV.
The ﬁrst step in the production process was to conduct growth
urves to determine the best virus strain and cell type to use. A
econd small batch was then produced under the optimal condi-
ions and used for inactivation and concentration analyses. Once
he inactivation and concentration procedure was  ﬁnalized, a large
atch of 2–10 T150-cm2 ﬂasks was produced, yielding 100–500
ials of antigen.Initially, titer was the performance indicator during the growth
curve analyses and the conditions that resulted in the highest titer
were assumed to also yield the highest VSAA in the MAC-ELISA.
However, some inactivated viruses with high titers had low VSAA.
In order to determine if the antigen degradation was caused by
the inactivation procedure, the VSAA of the live virus was  com-
pared to the inactivated antigen by MAC-ELISA. In some cases
the VSAA was unacceptably low for both the live and inactivated
virus, and the highest titers did not necessarily correspond to the
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ighest VSAA. Notably in CHIKV antigen production, the third anti-
en in the sequence, strains 181/25 and S27 both had titers of
0.3 log10 PFU/ml in C6/36 cells, but strain 181/25 had acceptable
SAA at a working antigen dilution of 1:4, whereas the VSAA of
HIKV strain S27 was unacceptable at any dilution (Table 2). There-
fter, viral growth curve samples were titrated but also evaluated
y MAC-ELISA, and the MAC-ELISA became the primary perfor-
ance indicator to evaluate antigen activity at every step in the
roduction process, including the live virus.
The differences in antigen activity between the two CHIKV
trains described above also highlight the importance of evalu-
ting a variety of virus strains during the initial growth curve
valuation. The prototype strain was generally used during SMB
ntigen production, and this strain was assumed to make the best,
ost reactive antigen in cell culture as well. However, as was
emonstrated with JCV and SINV antigen production, the proto-
ype strains were not as reactive as some of the non-prototype
trains from the reference collection. Only SINV strain AUS MRM
9, a non-prototype Australian isolate, reacted with the SINV IgM
ositive control. However, a caveat to this evaluation is that DVBD
oes not have a reference human anti-SINV IgM positive con-
rol serum. Instead, an alphavirus-group reactive mouse/human
himeric monoclonal antibody (cMAb) was used, which may
ave affected the reactivity of the various SINV strains tested
Thibodeaux et al., 2011). A SINV IgM-speciﬁc positive control from
 natural human infection may  produce different results. Addition-
lly, there were limited positive control reference sera with which
o evaluate the other antigens as well. Sera from a variety of geo-
raphical regions would be needed to determine if the difference
n reactivity was due to the virus strains.The cell type the viruses were cultured in also affected titer
nd antigen reactivity (Fig. 1 and Table 2). Vero cells secrete cell
ontact inhibition factors which slow cell division and maintain
he cell monolayer for 7–10 days (Earley and Johnson, 1988). Thusical Methods 208 (2014) 66–78
Vero cells are the preferred cell type to culture the slow-growing
ﬂaviviruses. Arboviruses such as alphaviruses and bunyaviruses,
with higher replication rates, are cultured efﬁciently in BHK-21
cells during the exponential growth phase, before the BHK-21 cells
reach conﬂuency, overgrow, and the cell sheet breaks up. Gener-
ally, arboviruses grow well in mosquito C6/36 cells, in which they
become persistently infected with very little, if any, observable CPE.
However, the VSAA from supernatant collected from C6/36 cell cul-
ture on multiple days was shown to be inconsistent and the NBR
increased over time. Therefore, C6/36 cells were chosen only if the
resulting antigen activity was  clearly superior to that of the other
cell types.
As the growth curves in Fig. 1 show, the ﬂaviviruses grew to
high titers in Vero cells for a longer period of time than in BHK-21
cells, allowing for 2–3 collections of supernatant, which increased
virus yield. Bunyaviruses replicated equally well in Vero and BHK-
21 cells, but the VSAAs were higher for bunyaviruses grown in
BHK-21c.13 cells. Alphaviruses also grew to high titers in both Vero
and BHK-21 cell culture; however there was considerable variabil-
ity between the VSAAs of the 3 alphaviruses in the different cell
types. For example, CHIKV strain S27 cultured in BHK-21c.15 cells
produced acceptable VSAA at a working antigen dilution of 1:4,
whereas CHIKV S27 grown in Vero cells was unreactive (Table 2).
These results illustrate the importance of conducting growth curves
in a variety of cells to determine the optimal cell type to use in
antigen production.
Chemical compounds and radiation have been used to destroy
the ability of viruses to infect cells, including BPL, formalin, hydro-
gen peroxide, sarkosyl, aziridine compounds, ultraviolet light, and
gamma  irradiation (Amanna et al., 2012; Brand and Allen, 1970;
Brown, 2001; Hearn and Dawson, 1961; Hiatt, 1964; Nims et al.,
2011; Piret et al., 2002b). For inactivated viral vaccines and anti-
gens used as reagents in immunoassays, it is also essential that
antigenic reactivity is preserved (Sabin, 1943). Because large vol-
umes of over 50 different antigens are produced at DVBD, virus
inactivation methods were needed that required little downstream
processing such as puriﬁcation or removal of residue. The methods
also needed to be effective to inactivate large volumes of live virus,
as antigen in this procedure is concentrated to a standard working
dilution after inactivation, and not before, as in other applications.
BPL has been used for inactivation of bacteria, fungi, and viruses,
as well as disinfection and sterilization, and has been widely used
to inactivate viral vaccines and antigens used in serological assays
(French and McKinney, 1964). BPL is an alkylating agent that mod-
iﬁes the structure of nucleic acids and proteins, and can cause
DNA-protein cross-linking (Lawrence, 2000; Uittenbogaard et al.,
2011; Bonnafous et al., 2014). The efﬁciency of BPL is dose-speciﬁc
and specimen-dependent, as accessibility for BPL molecules is
related to a diffusion gradient across the viral membrane (French
and McKinney, 1964). High BPL concentrations are required to
reach the most buried parts of the virus, and differences in BPL dif-
fusion within the virus may in part explain the differences reported
in the literature on the BPL concentration required to inactivate a
speciﬁc virus. Described as the “tailing phenomenon,” the bulk of
the virus is rapidly inactivated by a small concentration of BPL, but
a disproportionately larger concentration is required to inactivate
the residual active virus (Logrippo, 1960; French and McKinney,
1964). Although BPL efﬁciency depends on the corresponding alter-
ations of the viral structures and higher BLP concentrations will
completely inactivate the virus, over-inactivation by BPL can mod-
ify viral proteins, resulting in loss or increase of antigenicity (French
and McKinney, 1964; Uittenbogaard et al., 2011; Bonnafous et al.,
2014).
DVBD ADB has used BPL to inactivate viruses because it is inex-
pensive and easy to obtain and use. In addition, BPL hydrolyzes in
aqueous solution; its activity is self-limiting and there is no residual
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PL that needs to be removed. However, considerable batch-to-
atch inconsistency following inactivation by BPL was  previously
bserved. Complete batches had been rendered unusable as the
ntigen appeared to be degraded, resulting in a loss of VSAA, or
he NBR rose above the acceptable limit. Because of this, the opti-
al  virus inactivation method was determined empirically with
 range of BPL concentrations. Finding the correct concentration
f BPL was a balance between using a high enough concentration
o completely inactivate the virus with no or minimal reduction
n VSAA, and keeping the NBR within the acceptable range, par-
icularly after concentration. The tailing phenomenon was seen
uring BPL treatment as well (most notably with the alphaviruses),
n which the inactivation kinetics did not decrease linearly to zero,
ut tapered off below the threshold of detection with persistence
f low levels of viable virus particles in unconcentrated material;
ost-concentration, these particles were concentrated above the
hreshold of detection.
YFV treated with increasing doses of BPL resulted in lowered
SAA and increased NBR, and at the higher BPL concentrations
0.1%), the NBR of the YFV antigen rose above the acceptable limit
Table 1A). In contrast, the NBRs remained low at all BPL concen-
rations for the remaining ﬂaviviruses, SLEV and POWV (Table 1B
nd C, respectively). BPL was most effective at inactivating the
hree bunyaviruses. There was minimal loss of VSAA, and the NBRs
ere low and stable, even at the highest concentration of 0.1%
PL (Table 1G–I). Interestingly, similar to work described previ-
usly by French and McKinney (1964), VSAAs of some of the viruses
tudied here increased following BPL treatment, with the greatest
nhancement seen with CHIKV, MAYV, and LACV. Presumably, the
PL causes conformational changes in the envelope protein that
xposes or “opens-up” the antigenic epitopes recognized in the
AC-ELISA (Table 1D, 1E, and 1G, respectively). However, higher
oncentrations of BPL tended to generate higher NBR, most notably
or CHIKV and MAYV, as it did with YFV, and lower concentrations
id not completely inactivate these viruses.
To determine if the NBR was due to residual BPL, the BPL was
ubjected to complete hydrolysis following treatment of SLEV and
HIKV (Table 3). BPL-treated SLEV did not have high NBR initially,
nd hydrolysis had little effect on further lowering NBR. The NBR of
HIKV did decrease, but the VSAA also decreased, most likely due to
ntigen degradation after being held at 37 ◦C for an additional 2 h, as
as been shown previously (French and McKinney, 1964). Whereas
he NBR of CHIKV decreased to the acceptable range after hydroly-
is, this antigen was not concentrated, and the NBR often increases
fter concentration. BPL hydrolysis will be further investigated in
PL-treated YFV and CHIKV to determine if the NBR remains in
he acceptable range following concentration. Therefore, while BPL
emained the ﬁrst-line method of inactivation, additional inactiva-
ion methods were needed for CHIKV and YFV.
Inactivation by gamma-irradiation has advantages over BPL, as
here are no chemicals added to the supernatant which might inter-
ere with antigen activity by changing pH or causing NBR. In addi-
ion, the virus remains frozen throughout the irradiation procedure,
reventing the degradation of labile viruses, as can occur when
hese viruses are held at higher temperatures for extended periods
f time. Unfortunately, the process is expensive and a dedicated
adiation facility and certiﬁed personnel are required, limiting its
vailability. Consequently, gamma  irradiation analysis was gener-
lly performed on viral material for which BPL was an inadequate
nactivation method. Gamma  irradiation modiﬁes nucleic acids by
ausing base mutations, strand cross-linking, and strand breakage,
ut also generates free radicals and peroxides that can modify the
ntigenic protein epitopes (Nims et al., 2011). Consequently, kill
urves, or treatment with radiation doses ranging from 1 to 6 Mrad,
ere performed to determine the dose of radiation needed to com-
letely inactivate the virus but not compromise the antigen activity.ical Methods 208 (2014) 66–78 77
Because BPL-treated YFV produced an unacceptable antigen, it
was the ﬁrst to be evaluated by gamma  irradiation. At the high-
est dose of 5 Mrad, YFV was completely inactivated and there was
very low NBR, although some decrease in VSAA did occur. The
alphaviruses were also treated with gamma-irradiation but there
was residual infectivity (1–2 log10 PFU/ml) at 5–6 Mrad. Similar to
BPL treatment, gamma  irradiation increased alphavirus antigen
reactivity, possibly by changing antigen conformation to expose the
antigenic epitopes by the same mechanism as BPL (Table 1D–F).
For problematic viruses such as CHIKV, in which BPL treatment
resulted in unacceptably high NBR and gamma  irradiation did not
completely inactivate the virus, a combination of the two methods
proved effective. CHIKV strain S27 was ﬁrst treated with 5.5 Mrad
which lowered the titer to ≤2 log10 PFU/ml, and then treated with
≤0.05% BPL, which inactivated the virus but did not increase the
NBR above the acceptable limit.
None of the other inactivation methods were suitable. Either
they did not inactivate the virus or the antigen activity was
destroyed. Aziridine compounds such as binary ethylenimine (BEI)
were not evaluated, as BEI did not have any advantages over BPL
and vaccines inactivated by BEI have been shown to have a short
shelf-life of ≤2 years (Barteling, 2002).
At DVBD ADB, inactivated antigens are concentrated to a
standard working dilution of ∼1:160 and then aliquoted into vials
and lyophilized. In any concentration method there is some loss
of product, but it should be minimized as much as possible. Cen-
trifugal ﬁlters yielded higher VSAA and lower NBR compared to
ultracentrifugation, as antigen remained in the retentate in the
centrifugal ﬁlter method, whereas there was likely some loss
of ultracentrifuged pelleted antigen when the supernatant was
removed. In addition, the ultracentrifuged antigen pellet did not
fully re-solubilize in the resuspension buffer. Subsequently, cen-
trifugal ﬁlters are used to concentrate all antigen preparations, even
though more hands-on time is required to process large antigen
volumes (Fig. 2).
Arboviruses are sensitive to acidic conditions, whereas alkaline
conditions tend to preserve arbovirus viability (Beaty et al., 1995;
Brand and Allen, 1970). To optimize the storage buffer, concen-
trated YFV and SLEV antigen were resuspended in two different
buffers, 0.1 M trizma/BS (pH 9.0) and 1× PBS (pH 7.4), and anti-
gen activity was  compared. Working antigen dilutions tended to be
higher when antigens were resuspended in 0.1 M trizma/BS buffer
compared to 1× PBS, suggesting that the more alkaline pH of the
0.1 M trizma/BS buffer helped contribute to antigen preservation.
However, additional experiments would need to be performed to
determine whether antigen preservation was due primarily to pH
or whether the actual buffer components contributed as well. A
future experiment to help discern this may  consist of resuspending
concentrated antigen in 0.1 M trizma/BS with a more acidic pH and
1× PBS with a more alkaline pH.
Most concentrated antigens demonstrated higher working anti-
gen dilutions when resuspended in 0.1 M trizma/BS, although SLEV
antigen concentrated by centrifugal ﬁlters and resuspended in
either 0.1 M trizma/BS or 1× PBS had equivalent working antigen
dilutions of 1:80. This lack of difference may be due to the smaller
volume of buffer added to the retentate following ﬁltration, in con-
trast to the complete removal of cell culture supernatant and buffer
exchange that occurred during ultracentrifugation.
Concomitant with recent global arbovirus emergence and re-
emergence, there has been an increase in demand for arbovirus
diagnostic testing and the availability of reagents, both in terms
of the variety of arboviruses tested as well as the amount of
reagents needed. Lack of commercial sources for arbovirus antigens
has necessitated increased production in the DVBD ADB reference
laboratory. The development of the cell culture arbovirus anti-
gen production algorithm and optimization of the methods and
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rocesses will enhance the capacity of the reference laboratory to
espond to the changing needs of the diagnostic laboratory. In addi-
ion, this study illustrates the importance of optimizing the antigen
roduction procedure for each virus and evaluating antigen perfor-
ance in the end-use assay at every step in the production process.
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